178 related articles for article (PubMed ID: 23300174)
1. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
[No Abstract] [Full Text] [Related]
2. BRAF inhibition in refractory hairy-cell leukemia.
Dietrich S; Glimm H; Andrulis M; von Kalle C; Ho AD; Zenz T
N Engl J Med; 2012 May; 366(21):2038-40. PubMed ID: 22621641
[No Abstract] [Full Text] [Related]
3. Vemurafenib for relapsed or refractory hairy-cell leukaemia.
Baker H
Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26387749
[No Abstract] [Full Text] [Related]
4. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.
Follows GA; Sims H; Bloxham DM; Zenz T; Hopper MA; Liu H; Bench A; Wright P; Van't Veer MB; Scott MA
Br J Haematol; 2013 Apr; 161(1):150-3. PubMed ID: 23278307
[No Abstract] [Full Text] [Related]
5. Efficacy of vemurafenib in hairy-cell leukemia.
Samuel J; Macip S; Dyer MJ
N Engl J Med; 2014 Jan; 370(3):286-8. PubMed ID: 24428489
[No Abstract] [Full Text] [Related]
6. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
[TBL] [Abstract][Full Text] [Related]
7. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.
Maurer H; Haas P; Wengenmayer T; Lübbert M; Duyster J; Zeiser R
Ann Hematol; 2014 Aug; 93(8):1439-40. PubMed ID: 24337488
[No Abstract] [Full Text] [Related]
8. Hairy cell leukemia.
Dearden C
Best Pract Res Clin Haematol; 2015 Dec; 28(4):163-5. PubMed ID: 26614893
[No Abstract] [Full Text] [Related]
9. Hairy cell leukemia: Past, present and future.
Getta BM; Park JH; Tallman MS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
[TBL] [Abstract][Full Text] [Related]
10. BRAF inhibitor therapy in HCL.
Dietrich S; Zenz T
Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
[TBL] [Abstract][Full Text] [Related]
11. Hairy cell leukemia: update and current therapeutic approach.
Salam L; Abdel-Wahab O
Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
[TBL] [Abstract][Full Text] [Related]
12. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.
Munoz J; Schlette E; Kurzrock R
J Clin Oncol; 2013 Jul; 31(20):e351-2. PubMed ID: 23733763
[No Abstract] [Full Text] [Related]
13. Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.
Bhangoo MS; Saven A
Leuk Lymphoma; 2019 May; 60(5):1331-1333. PubMed ID: 30322325
[No Abstract] [Full Text] [Related]
14. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.
Dietrich S; Pircher A; Endris V; Peyrade F; Wendtner CM; Follows GA; Hüllein J; Jethwa A; Ellert E; Walther T; Liu X; Dyer MJ; Elter T; Brummer T; Zeiser R; Hermann M; Herold M; Weichert W; Dearden C; Haferlach T; Seiffert M; Hallek M; von Kalle C; Ho AD; Gaehler A; Andrulis M; Steurer M; Zenz T
Blood; 2016 Jun; 127(23):2847-55. PubMed ID: 26941398
[TBL] [Abstract][Full Text] [Related]
15. [Successful use of vemurafenib in a patient with resistant hairy cell leukemia].
Urnova ES; Al'-Radi LS; Kuz'mina LA; Kariakina AA; Kovrigina AM; Dvirnyk VN; Iakutik IA; Sudarikov AB; Parovichnikova EN; Savchenko VG
Ter Arkh; 2013; 85(7):76-8. PubMed ID: 24137951
[TBL] [Abstract][Full Text] [Related]
16. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Dietrich S; Hüllein J; Hundemer M; Lehners N; Jethwa A; Capper D; Acker T; Garvalov BK; Andrulis M; Blume C; Schulte C; Mandel T; Meissner J; Fröhling S; von Kalle C; Glimm H; Ho AD; Zenz T
J Clin Oncol; 2013 Jul; 31(19):e300-3. PubMed ID: 23690412
[No Abstract] [Full Text] [Related]
17. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
Kaplan HG
J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.
Ji G; Qian Y
Clin Genitourin Cancer; 2017 Aug; 15(4):e719-e721. PubMed ID: 28024948
[No Abstract] [Full Text] [Related]
19. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
